annexin a1 peptide

**Annexin A1 peptide** refers to synthetic peptides derived from the N-terminal region of the Annexin A1 protein (notably Ac2-26, residues 2-26; and MC16, residues 1-15). These peptides mimic key anti-inflammatory and pro-resolving functions of the endogenous Annexin A1 protein. Mechanistically, annexin A1 peptides activate formyl peptide receptors, especially **FPR1** and **FPR2**, leading to inhibition of neutrophil migration, reduction of inflammation, promotion of wound healing, and facilitation of tissue repair by affecting cell migration and redox signaling. They show therapeutic effects in various inflammation-driven models, such as ischemia–reperfusion injury, airways inflammation, and potentially cancer vasculature[2][4][5][9]. No products are formally approved for human use; these compounds are **experimental research peptides** used primarily in preclinical animal models and mechanistic research. The main therapeutic interest is in cardiovascular, microvascular, inflammatory, and wound repair indications[1][2][5][6][9].

Other names

annexin a1 peptideannexin-A1 peptideannexin-A-1 peptideannexin-A 1 peptideAc2-26Ac-2-26Ac 2-26MC16MC-16MC 16